About LYNNAGEN
Clinical genomics software built around reviewable evidence.
LYNNAGEN is being developed for clinical geneticists, molecular genetics laboratories, molecular pathologists, and diagnostic programs that need structured evidence without losing professional judgment.
Why LYNNAGEN
Genomic interpretation often requires the reviewer to reconcile variant identity, public assertions, disease mechanism, phenotype, population data, functional evidence, technical quality, and source provenance. LYNNAGEN is designed to place those layers in one review workspace while keeping their meanings distinct.
Product principles
- Five-tier pathogenicity remains the primary classification dimension.
- Patient relevance is reviewed separately from intrinsic pathogenicity.
- Technical QC remains independently auditable.
- No public classification is not automatically treated as VUS.
- Unsafe or unresolved variant identity is not forced into a five-tier result.
- The qualified clinician or laboratory reviewer remains the final decision-maker.
Who it is for
Clinical genetics, molecular diagnostics, molecular pathology, and diagnostic laboratory teams evaluating evidence-intensive germline workflows.